Efficacy of Initial Treatment with Clevudine in Naive Patients with Chronic Hepatitis B
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Clevudine, a pyrimidine nucleoside analogue, has potent antiviral effects in patients with chronic viral hepatitis B (CHB). We report the efficacy of initial treatment with clevudine in naïve patients with CHB living in Daejeon and Chungcheong Province, South Korea. Methods: One hundred five adults with CHB were administered 30 mg of clevudine per day for an average of 51 weeks. We evaluated viral markers and liver biochemistry retrospectively every 3 months. Results: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and hepatitis B virus (HBV) DNA before the treatment were 184 ± 188 IU/L, 150 ± 138 IU/L, and 7.1 ± 1.2 log copies/mL, respectively. Undetectable rates (< 60 IU/mL) of DNA were 36.2%, 68.9%, 83.6%, 76.2%, and 75.8% at 12, 24, 36, 48, and 60 weeks, respectively. Seroconversion rates were 9.1%, 13.6%, 24.6%, 26.5%, and 26.1% and ALT normalization rates were 64.5%, 78.1%, 87.9%, 90.0% at 12, 24, 36, and 48 weeks, respectively. Six patients (5.7%) had a viral breakthrough. Conclusions: Clevudine is a useful drug in the initial treatment of patients with CHB, with a potent antiviral effect and low incidence of viral breakthrough. (Korean J Intern Med 2010;25:372-376)
Abstract
Background/Aims: Clevudine, a pyrimidine nucleoside analogue, has potent antiviral effects in patients with chronic viral hepatitis B (CHB). We report the efficacy of initial treatment with clevudine in naïve patients with CHB living in Daejeon and Chungcheong Province, South Korea. Methods: One hundred five adults with CHB were administered 30 mg of clevudine per day for an average of 51 weeks. We evaluated viral markers and liver biochemistry retrospectively every 3 months. Results: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and hepatitis B virus (HBV) DNA before the treatment were 184 ± 188 IU/L, 150 ± 138 IU/L, and 7.1 ± 1.2 log copies/mL, respectively. Undetectable rates (< 60 IU/mL) of DNA were 36.2%, 68.9%, 83.6%, 76.2%, and 75.8% at 12, 24, 36, 48, and 60 weeks, respectively. Seroconversion rates were 9.1%, 13.6%, 24.6%, 26.5%, and 26.1% and ALT normalization rates were 64.5%, 78.1%, 87.9%, 90.0% at 12, 24, 36, and 48 weeks, respectively. Six patients (5.7%) had a viral breakthrough. Conclusions: Clevudine is a useful drug in the initial treatment of patients with CHB, with a potent antiviral effect and low incidence of viral breakthrough. (Korean J Intern Med 2010;25:372-376)
참고문헌 (15)
- Lee KS, "Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy", Intervirology, 50, pp.296~302 (2007)
- Locarnini S, "Molecular virology and the development of resistant mutants: implications for therapy", Semin Liver Dis, 25, pp.9~19 (2005)
- Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
- Matthews SJ, "Entecavir for the treatment of chronic hepatitis B virus infection", Clin Ther, 28, pp.184~203 (2006)
- 고경현, "라미부딘 치료 후 클레부딘으로 전환한 만성 B형간염 환자에서 발생된 클레부딘 내성 1예: 연관 염기서열 분석", 대한소화기학회지, 52(5), pp.325~328 (2008), 대한소화기학회
- Liu SH, "Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-Larabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase", Antimicrob Agents Chemother, 42, pp.833~839 (1998)
- Marcellin P, "A phase II doseescalating trial of clevudine in patients with chronic hepatitis B", Hepatology, 40, pp.140~148 (2004)
- Lee HS, "A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B", Hepatology, 43, pp.982~988 (2006)
- Yoo BC, "Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAgpositive chronic hepatitis B", Hepatology, 45, pp.1172~1178 (2007)
- Yoo BC, "Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression", Hepatology, 46, pp.1041~1048 (2007)
- Lim SG, "Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B", Aliment Pharmacol Ther, 27, pp.1282~1292 (2008)
- Niu C, "Clevudine is efficiently phosphorylated to the active triphosphate form in primary human hepatocytes", Antivir Ther, 13, pp.263~269 (2008)
- 김민환, "만성 B형간염에서 클레부딘의 48주 치료 효과", The Korean Journal of Hepatology, 15(3), pp.331~337 (2009), 대한간학회
- Fischer KP, "Lamivudine resistance in hepatitis B: mechanisms and clinical implications", Drug Resist Updat, 4, pp.118~128 (2001)
- Ferenci P, "Treatment of chronic viral hepatitis", Best Pract Res Clin Gastroenterol, 18, pp.113~120 (2004)